Search Results

-positives. PET/CT may be more useful than conventional CT in the workup of patients who have relatively high pretest probabilities of occult metastatic disease (eg, patients with stage IIIB and IIIC melanoma). Treatment Adjuvant Therapy High

HER2 copy number is less than 4 signals/cell is that….” 2 Based on the pre-2018 ASCO/CAP HER2 classification, whether being used as adjuvant therapy or therapy for metastatic HER2-positive disease, the FDA-approved anti-HER2 therapies offer truly

, only 6.3% of high risk stage II and 45.5% of stage III patients received adjuvant therapy. Data showed 100% compliance with initiation of adjuvant 5-FU based chemotherapy within 12 weeks post surgery, which is recommended in high risk stage II and III

treatment with the best chance of success. Adjuvant Therapy Although 11 agents have been approved by the FDA for CRC, only 3 are used in the adjuvant setting (fluorouracil [5-FU], capecitabine, and oxaliplatin) and only 2 (cetuximab and panitumumab

unresectable) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study

-treatment assessments, consultations, considerations, neoadjuvant and adjuvant therapy and survivorship care. Oncology provider survey return rate was 25%. Results indicated satisfaction but changes needed to pathway design and content. Modified pathways were

determine the number of positive lymph nodes as an independent prognostic indicator in Stage II colorectal carcinoma, which prompts adjuvant therapy in these patients. This study aimed to assess the average number of lymph nodes in post-neoadjuvant rectal

) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study purposes, a cycle

1990 ; 66 : 56 – 61 . 7 Whittington R Bryer MP Haller DG . Adjuvant therapy of resected adenocarcinoma of the pancreas . Int J Radiat Oncol Biol Phys 1991 ; 21 : 1137 – 1143 . 8 Abrams RA . Adjuvant therapy for pancreatic

the addition of adjuvant therapy . J Clin Oncol 2005 ; 23 : 7236 – 7237 . 13. Wilson LD Gruber SB . Merkel cell carcinoma and the controversial role of adjuvant radiation therapy: clinical choices in the absence of statistical evidence